JP2016512204A - B型肝炎ワクチン - Google Patents
B型肝炎ワクチン Download PDFInfo
- Publication number
- JP2016512204A JP2016512204A JP2015561921A JP2015561921A JP2016512204A JP 2016512204 A JP2016512204 A JP 2016512204A JP 2015561921 A JP2015561921 A JP 2015561921A JP 2015561921 A JP2015561921 A JP 2015561921A JP 2016512204 A JP2016512204 A JP 2016512204A
- Authority
- JP
- Japan
- Prior art keywords
- hbsag
- cpg
- hbcag
- odn
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 title description 13
- 229940124736 hepatitis-B vaccine Drugs 0.000 title description 13
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims abstract description 169
- 239000000427 antigen Substances 0.000 claims abstract description 98
- 102000036639 antigens Human genes 0.000 claims abstract description 98
- 108091007433 antigens Proteins 0.000 claims abstract description 98
- 208000015181 infectious disease Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 230000001404 mediated effect Effects 0.000 claims abstract description 14
- 101710132601 Capsid protein Proteins 0.000 claims description 178
- 208000002672 hepatitis B Diseases 0.000 claims description 78
- 241000700721 Hepatitis B virus Species 0.000 claims description 64
- 230000028993 immune response Effects 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 33
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 230000006058 immune tolerance Effects 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 9
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 8
- 230000004075 alteration Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 103
- 238000000034 method Methods 0.000 abstract description 29
- 239000012634 fragment Substances 0.000 abstract description 20
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 7
- 125000005642 phosphothioate group Chemical group 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 59
- 239000002953 phosphate buffered saline Substances 0.000 description 37
- 241000699666 Mus <mouse, genus> Species 0.000 description 36
- 230000003053 immunization Effects 0.000 description 35
- 150000001413 amino acids Chemical class 0.000 description 34
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 34
- 238000002649 immunization Methods 0.000 description 34
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 27
- 229940079593 drug Drugs 0.000 description 25
- 239000002671 adjuvant Substances 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 238000011830 transgenic mouse model Methods 0.000 description 20
- 241000699660 Mus musculus Species 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- 229920001184 polypeptide Polymers 0.000 description 18
- 230000002147 killing effect Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 230000001681 protective effect Effects 0.000 description 16
- 102000004388 Interleukin-4 Human genes 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 15
- 108010074328 Interferon-gamma Proteins 0.000 description 14
- -1 SEQ ID NO: 2 amino acids Chemical group 0.000 description 14
- 102100037850 Interferon gamma Human genes 0.000 description 13
- 230000007969 cellular immunity Effects 0.000 description 13
- 230000004727 humoral immunity Effects 0.000 description 13
- 210000000447 Th1 cell Anatomy 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 11
- 108090000978 Interleukin-4 Proteins 0.000 description 11
- 230000024245 cell differentiation Effects 0.000 description 11
- 108010067902 Peptide Library Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 210000003141 lower extremity Anatomy 0.000 description 10
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 8
- 230000029662 T-helper 1 type immune response Effects 0.000 description 8
- 230000029069 type 2 immune response Effects 0.000 description 8
- 229940028617 conventional vaccine Drugs 0.000 description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000004241 Th2 cell Anatomy 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 4
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000009739 binding Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006057 immunotolerant effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 241000272194 Ciconiiformes Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229940127073 nucleoside analogue Drugs 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012048 reactive intermediate Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108091036055 CccDNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101710142246 External core antigen Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 241000283925 Spermophilus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000007185 Stork enamine alkylation reaction Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 208000036141 Viral hepatitis carrier Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960002348 hepatitis b surface antigen vaccine Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
i)HBsAg、前記抗原のフラグメント、前記抗原の変異体、またはその少なくとも2種の混合物、
ii)HBcAg、前記抗原のフラグメント、前記抗原または前記抗原のフラグメントの変異体、またはその少なくとも2種の混合物、
iii)シーケンスには2つまたは2つ以上のコピーされた5’−NTCGTT−3’配列モチーフを有し、長さが20〜25の塩基である、ホスホロチオアートオリゴヌクレオチドであるCpG−ODN
を含む。前記オリゴヌクレオチドは5’−TCG TTC GTT CGT TCG TTC GTT−3’、5’−TCG TTC GTT CGT TCG TTC GTT CGT T−3’、5’−TCG TCG TCG TCG TCG TCG TCG−3’または5’−TCC ATG ACG TTC CTG ACG TT−3’の塩基シーケンスから選ばれることが好ましく、5’−TCG TTC GTT CGT TCG TTC GTT−3’がより好ましい。
別に定義されない場合、本文に使用される全ての技術用語は当業者に理解される意味を有する。本分野の定義及び用語に関し、当業者はCurrent Protocols in Molecular Biology(Ausubel)を参考にできる。アミノ酸残基の略号は20の常用L−アミノ酸を指す標準的な3字及び/または1字のコードである。
Claims (14)
- i)B型肝炎表面抗原(HBsAg)、
ii)B型肝炎コア抗原(HBcAg)、
iii)CpGオリゴデオキシヌクレオチド(CpG−ODN)、
及び/またはiv)必要ならば薬学的に許容される担体
を含む、医薬組成物。 - 予防用または治療用ワクチンとして用いられる、請求項1に記載の医薬組成物。
- 前記HBsAgがSEQ ID NO:1に示されるシーケンスを有する、請求項1または2に記載の医薬組成物。
- 前記HBcAgがSEQ ID NO:2に示されるシーケンスを有する、請求項1〜3のいずれか1項に記載の医薬組成物。
- 前記CpG−ODNがチオリン酸エステル結合を含み、好ましくは前記CpG−ODNがトータルホスホロチオアートオリゴデオキシヌクレオチドである、請求項1〜4のいずれか1項に記載の医薬組成物。
- 前記CpG−ODNが2つまたはより多くの5’−NTCGTT−3’配列モチーフを含む、請求項1〜5のいずれか1項に記載の医薬組成物。
- 前記CpG−ODNの長さが15〜35のヌクレオチド、好ましくは20〜25のヌクレオチドである、請求項1〜6のいずれか1項に記載の医薬組成物。
- 前記CpG−ODNが5’−TCG TTC GTT CGT TCG TTC GTT−3’(SEQ ID NO:3)、5’−TCG TTC GTT CGT TCG TTC GTT CGT T−3’(SEQ ID NO:4)、5’−TCG TCG TCG TCG TCG TCG TCG−3’(SEQ ID NO:5)及び5’−TCC ATG ACG TTC CTG ACG TT−3’(SEQ ID NO:6)から選ばれるシーケンスを有し、好ましくは、前記CpG−ODNが5’−TCG TTC GTT CGT TCG TTC GTT−3’(SEQ ID NO:3)のシーケンスを有する、請求項1〜7のいずれか1項に記載の医薬組成物。
- 前記成分i)、ii)及びiii)の間の相対重量比範囲が1:0.2〜5:1〜50で、好ましくは1:1〜5:2〜15である、請求項1〜8のいずれか1項に記載の医薬組成物。
- 請求項1〜9のいずれか1項に記載の医薬組成物及びその添付文書を含むキット。
- 対象においてHBV感染及び/またはHBV介在の病気、好ましくは、B型肝炎、肝硬変及び肝癌から選ばれるHBV感染及び/またはHBV介在の病気を処置する医薬の製造における、請求項1〜9のいずれか1項に記載の医薬組成物の使用。
- HBVに対する免疫応答を発生する医薬の製造における、請求項1〜9のいずれか1項に記載の医薬組成物の使用。
- 抗HBcAg抗体に亜型変転を発生させる医薬の製造における、請求項1〜9のいずれか1項に記載の医薬組成物の使用。
- B型肝炎ウイルス免疫寛容を突破する医薬の製造における、請求項1〜9のいずれか1項に記載の医薬組成物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310080863.X | 2013-03-13 | ||
CN201310080863.XA CN104043120B (zh) | 2013-03-13 | 2013-03-13 | 乙型肝炎疫苗 |
PCT/CN2014/072570 WO2014139359A1 (zh) | 2013-03-13 | 2014-02-26 | 乙型肝炎疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016512204A true JP2016512204A (ja) | 2016-04-25 |
JP6499592B2 JP6499592B2 (ja) | 2019-04-10 |
Family
ID=51496840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015561921A Active JP6499592B2 (ja) | 2013-03-13 | 2014-02-26 | B型肝炎ワクチン |
Country Status (6)
Country | Link |
---|---|
US (1) | US9878035B2 (ja) |
EP (1) | EP2974740B1 (ja) |
JP (1) | JP6499592B2 (ja) |
CN (1) | CN104043120B (ja) |
HK (1) | HK1218872A1 (ja) |
WO (1) | WO2014139359A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022516041A (ja) * | 2018-12-24 | 2022-02-24 | 遠大賽威信生命科学(南京)有限公司 | B型肝炎を治療するための薬物製剤、その製造方法及び用途 |
JP7555929B2 (ja) | 2018-12-24 | 2024-09-25 | 遠大賽威信生命科学(南京)有限公司 | B型肝炎を治療するための薬物製剤、その製造方法及び用途 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104873969B (zh) * | 2015-04-16 | 2018-06-19 | 南京赛威信生物医药有限公司 | 基于HBV PreS-S、C抗原及新型佐剂CpG的治疗性乙型肝炎疫苗 |
CA3023022A1 (en) * | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
CN107693788B (zh) * | 2017-08-21 | 2022-10-11 | 远大赛威信生命科学(南京)有限公司 | 一种用于预防或治疗乙型肝炎的药物组合物及其用途 |
GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
BR112022005687A2 (pt) | 2019-09-30 | 2022-06-21 | Gilead Sciences Inc | Vacinas contra o hbv e métodos para tratar o hbv |
JP2023506439A (ja) | 2019-12-13 | 2023-02-16 | 遠大賽威信生命科学(南京)有限公司 | 医薬組成物及びその用途 |
CN113058033B (zh) * | 2019-12-16 | 2024-07-09 | 远大赛威信生命科学(南京)有限公司 | 一种用于预防和治疗乙型肝炎的药物组合物及其用途 |
CN111728955A (zh) * | 2020-06-19 | 2020-10-02 | 中山大学 | 一种用于乙肝治疗的纳米颗粒及其制备方法和治疗性疫苗 |
CN114409802B (zh) * | 2020-12-31 | 2023-10-20 | 中国科学院微生物研究所 | 禽流感病毒三聚体亚单位疫苗及其应用 |
CN114437185B (zh) * | 2020-12-31 | 2023-06-27 | 中国科学院微生物研究所 | 冠状病毒三聚体亚单位疫苗及其应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008536515A (ja) * | 2005-04-18 | 2008-09-11 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | ワクチンの調製のためのb型肝炎ウイルス表面抗原の発現 |
JP2009507877A (ja) * | 2005-09-16 | 2009-02-26 | ライン ビオテヒ ゲゼルシャフト フューア ノイエ ビオテヒノロギシェ プロツェスェ ウント プロドゥクテ エムベーハー | 切り詰め型hbcコアタンパク質と、サポニンが主成分の免疫増進剤とを含有するワクチン |
CN101492672A (zh) * | 2008-01-23 | 2009-07-29 | 许洪林 | 具有免疫刺激活性的硫代寡聚脱氧核苷酸及其应用 |
CN101559224A (zh) * | 2008-04-18 | 2009-10-21 | 北京生物制品研究所 | 脊髓灰质炎疫苗 |
CN101675994A (zh) * | 2008-09-19 | 2010-03-24 | 齐鲁制药有限公司 | 治疗性疫苗制剂 |
WO2010120874A2 (en) * | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
JP2013505971A (ja) * | 2009-09-29 | 2013-02-21 | セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア | 治療上の免疫化後の細胞性刺激のためのb型肝炎ウイルス抗原製剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4547367A (en) | 1983-12-20 | 1985-10-15 | The United States Of America As Represented By The Department Of Health And Human Services | Hepatitis B core antigen vaccine |
US6689363B1 (en) * | 1992-01-29 | 2004-02-10 | Epimmune Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
US7323331B2 (en) * | 2000-08-11 | 2008-01-29 | Advanced Life Science Institute, Inc. | Method for detecting or assaying HBV |
MY163512A (en) * | 2009-09-03 | 2017-09-15 | Pfizer Vaccines Llc | Pcsk9 vaccine |
CN102462840B (zh) * | 2010-11-09 | 2014-03-19 | 南通生物科技园开发投资有限公司 | 乙肝治疗性疫苗 |
-
2013
- 2013-03-13 CN CN201310080863.XA patent/CN104043120B/zh active Active
-
2014
- 2014-02-26 EP EP14765662.3A patent/EP2974740B1/en active Active
- 2014-02-26 US US14/773,829 patent/US9878035B2/en active Active
- 2014-02-26 JP JP2015561921A patent/JP6499592B2/ja active Active
- 2014-02-26 WO PCT/CN2014/072570 patent/WO2014139359A1/zh active Application Filing
-
2016
- 2016-06-16 HK HK16106930.2A patent/HK1218872A1/zh unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008536515A (ja) * | 2005-04-18 | 2008-09-11 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | ワクチンの調製のためのb型肝炎ウイルス表面抗原の発現 |
JP2009507877A (ja) * | 2005-09-16 | 2009-02-26 | ライン ビオテヒ ゲゼルシャフト フューア ノイエ ビオテヒノロギシェ プロツェスェ ウント プロドゥクテ エムベーハー | 切り詰め型hbcコアタンパク質と、サポニンが主成分の免疫増進剤とを含有するワクチン |
CN101492672A (zh) * | 2008-01-23 | 2009-07-29 | 许洪林 | 具有免疫刺激活性的硫代寡聚脱氧核苷酸及其应用 |
CN101559224A (zh) * | 2008-04-18 | 2009-10-21 | 北京生物制品研究所 | 脊髓灰质炎疫苗 |
CN101675994A (zh) * | 2008-09-19 | 2010-03-24 | 齐鲁制药有限公司 | 治疗性疫苗制剂 |
WO2010120874A2 (en) * | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
JP2013505971A (ja) * | 2009-09-29 | 2013-02-21 | セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア | 治療上の免疫化後の細胞性刺激のためのb型肝炎ウイルス抗原製剤 |
Non-Patent Citations (1)
Title |
---|
XU, HONGLIN ET AL.: "CpG-ODN is a potential candidate adjuvant for human vaccines", ZHONGHUS YIXUE XAZHI, vol. 82, no. 8, JPN7016002633, 2002, pages 553 - 556, ISSN: 0003395201 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022516041A (ja) * | 2018-12-24 | 2022-02-24 | 遠大賽威信生命科学(南京)有限公司 | B型肝炎を治療するための薬物製剤、その製造方法及び用途 |
JP7555929B2 (ja) | 2018-12-24 | 2024-09-25 | 遠大賽威信生命科学(南京)有限公司 | B型肝炎を治療するための薬物製剤、その製造方法及び用途 |
Also Published As
Publication number | Publication date |
---|---|
EP2974740A4 (en) | 2016-08-24 |
EP2974740A1 (en) | 2016-01-20 |
US9878035B2 (en) | 2018-01-30 |
EP2974740B1 (en) | 2019-06-19 |
US20160136264A1 (en) | 2016-05-19 |
WO2014139359A1 (zh) | 2014-09-18 |
CN104043120A (zh) | 2014-09-17 |
JP6499592B2 (ja) | 2019-04-10 |
CN104043120B (zh) | 2017-05-31 |
HK1218872A1 (zh) | 2017-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6499592B2 (ja) | B型肝炎ワクチン | |
JP6629195B2 (ja) | ウイルス免疫療法用の医薬組成物およびその使用 | |
JP2023506439A (ja) | 医薬組成物及びその用途 | |
JP2019195328A (ja) | デングウイルスワクチンのための方法および組成物 | |
JP2017524682A (ja) | CpGオリゴヌクレオチドを含む医薬組成物 | |
WO2021214297A1 (en) | Immunization against sars-cov-related diseases | |
CN104873969B (zh) | 基于HBV PreS-S、C抗原及新型佐剂CpG的治疗性乙型肝炎疫苗 | |
CN117897487A (zh) | 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用 | |
ES2386369T3 (es) | Vacunas que comprenden la proteína de núcleo HBC truncado mas adyuvantes basados en saponina | |
US20220175912A1 (en) | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use | |
CN107693788B (zh) | 一种用于预防或治疗乙型肝炎的药物组合物及其用途 | |
US8691234B2 (en) | Vaccine formulation potentiated by the combination of DNA and an antigen | |
CA3119581A1 (en) | Immunogenic compositions for treatment of hepatitis b | |
CN114340666A (zh) | 环二核苷酸的新用途 | |
WO2008031878A1 (en) | A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases | |
Ramasamy | COVID-19 Vaccines for Optimizing Immunity in the Upper Respiratory Tract. Viruses 2023, 15, 2203 | |
CA3144319A1 (en) | Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b. | |
EP1902727A1 (de) | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170523 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170822 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171013 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180509 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180709 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20180727 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190315 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6499592 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |